Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

83.71 0.06

Overview

Share price change

24h

Current

Min

83.63

Max

83.77

Key metrics

By Trading Economics

Income

-5M

-128M

Sales

6.8M

11M

EPS

-1.23

Profit margin

-1,191.029

Employees

594

EBITDA

-5M

-127M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-1.79% downside

Dividends

By Acuity

Next Earnings

4 Aug 2026

Market Stats

By TradingEconomics

Market Cap

4.5B

8.9B

Previous open

83.65

Previous close

83.71

News Sentiment

By Acuity

51%

49%

240 / 340 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

23 Jul 2026, 23:51 UTC

News

Cavco Industries Inc. announced its first-quarter earnings release date, contributing to positive investor sentiment. Shares are higher in after-market trading.

23 Jul 2026, 23:51 UTC

News

Scholastic Corp shares fell in after-market trading following fourth-quarter results, where revenue of $476.1 million missed expectations and net income dropped to $9.4 million.

23 Jul 2026, 23:51 UTC

News
Social Media

Leidos Holdings shares are lower in after-market trading amid concerns over long-term revenue growth, despite a backlog of $48.37 billion.

23 Jul 2026, 23:51 UTC

News

Codexis Inc announced a public offering of common stock, contributing to a notable decline in shares during after-market trading.

23 Jul 2026, 23:51 UTC

News

PayPal shares are lower in after-market trading as Stripe and Advent assess acquisition options, with prior offers reportedly considered insufficient.

23 Jul 2026, 23:46 UTC

News

Delek US Holdings Inc declared a quarterly dividend of $0.255 per share, contributing to shares trading higher in after-market hours.

23 Jul 2026, 23:46 UTC

News
Social Media

CSX Corp shares rose in after-market trading following stronger-than-expected second-quarter results, with earnings of $0.54 per share and revenue of $3.94 billion.

23 Jul 2026, 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

23 Jul 2026, 23:41 UTC

Event
News

GE Healthcare appointed George Newcomb as interim CFO and reported $5.30 billion in second-quarter revenue, with shares higher in after-market trading.

23 Jul 2026, 23:41 UTC

News

Albertsons Companies reported revenue growth in Q1 2026, despite margin contraction. Shares are modestly higher in after-market trading since Thursday's close.

23 Jul 2026, 23:41 UTC

News

Charter Communications launched a private offer to exchange notes, potentially issuing up to $1.75 billion in new notes, with shares trading higher in after-market hours.

23 Jul 2026, 23:31 UTC

Social Media
Correlated Moves
News

Newmont Corporation's adjusted EPS of $2.10 missed estimates, with revenue at $6.12 billion, leading to a decline in after-market trading.

23 Jul 2026, 23:31 UTC

News

Appian Corp's digital application update for community services workers supports over 210,000 and processed more than $100 million, boosting shares in after-market hours.

23 Jul 2026, 23:26 UTC

News

Amgen Inc shares traded lower in after-market hours amid challenges in the biotechnology sector and increased credit risk perceptions in the investment-grade bond market.

23 Jul 2026, 23:26 UTC

News

Hims & Hers Health Inc shares are higher after an FDA advisory panel recommended easing restrictions on a popular peptide and Canaccord reiterated a Buy rating.

23 Jul 2026, 23:21 UTC

News

Robert Half shares are trading lower in after-market hours following a second-quarter revenue decline to $1.336 billion and a cautious outlook for Q3.

23 Jul 2026, 23:21 UTC

Social Media
News

Maxlinear Inc's shares fell in after-hours trading following second-quarter results, with net revenue of $168.8 million but diluted earnings of $0.02 per share.

23 Jul 2026, 23:21 UTC

News

McKesson Corp shares fell in after-market trading amid weakness in the Health Care Distributors sector, despite strong annual revenue and earnings growth.

23 Jul 2026, 23:02 UTC

ETF Constituents
News

Vanguard Large-Cap ETF gains after hours, supported by major holdings like Microsoft and Tesla, despite broader market declines from new tariffs announced by President Trump.

23 Jul 2026, 23:02 UTC

ETF Constituents
Social Media
News

Invesco QQQ Trust Series I rises in after-market trading, supported by positive sentiment from Intel's projected capital expenditures exceeding $20 billion.

23 Jul 2026, 23:02 UTC

Social Media
News

RingCentral's revenue of $657 million surpassed estimates, prompting a raised full-year guidance. Shares are higher in after-market trading, rebounding from an earlier session low.

23 Jul 2026, 23:02 UTC

Correlated Moves
News

Ovintiv Inc reported second-quarter earnings that missed expectations, with an EPS of $1.62. Shares are lower in after-market trading following the results.

23 Jul 2026, 23:02 UTC

Social Media
News

Appfolio Inc shares are lower in after-market trading following second-quarter earnings. Revenue guidance of $1.117 billion to $1.127 billion fell short of expectations.

23 Jul 2026, 23:02 UTC

News

Selective Insurance Group shares fell in after-hours trading following mixed second-quarter results, despite net income of $127.1 million and revenue of $1.39 billion.

23 Jul 2026, 23:02 UTC

News
Social Media

Comfort Systems USA reported strong Q2 earnings and revenue, but shares are trading lower in after-market hours, indicating a shift in market sentiment.

23 Jul 2026, 23:02 UTC

Social Media
News

Amkor Technology announced a $1.5 billion partnership with NVIDIA to enhance packaging capacity, boosting shares significantly in after-market hours.

23 Jul 2026, 23:02 UTC

Correlated Moves
News

ServiceNow shares are higher in after-market hours as Macquarie raised its price target to $110, reflecting positive market sentiment and sector dynamics.

23 Jul 2026, 23:02 UTC

Social Media
News

Intel Corp reported second-quarter revenue of $16.1 billion, exceeding expectations. The positive outlook has driven shares higher in after-market hours.

23 Jul 2026, 23:02 UTC

News

Boeing Co shares are lower in after-market trading after announcing the divestiture of its stake in HRL Laboratories, LLC, amid broader market pressures.

23 Jul 2026, 23:01 UTC

News
Social Media
Event

Tenet Healthcare Corp reported second-quarter adjusted EPS of $6.12, exceeding estimates. Shares are trading higher in after-market hours following strong earnings and raised guidance.

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

-1.79% downside

12 Months Forecast

Average 82.22 USD  -1.79%

High 95 USD

Low 55 USD

Based on 14 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

3

Buy

11

Hold

0

Sell

Sentiment

By Acuity

240 / 340 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat